ABSTRACT
Hepatoma is a malignant tumor that responds poorly to conventional therapies. Boron neutron capture therapy (BNCT) may provide a better way for hepatoma therapy. In this research, (10)B-enriched boric acid (BA, 99% (10)B) was used as the boron drug. A multifocal hepatic VX2 tumor-bearing rabbit model was used to study the mechanisms of BA-mediated BNCT. Autoradiography demonstrated that BA was selectively targeted to tumors and tumor vessels. Histopathological examination revealed the radiation damage to tumor-bearing liver was concentrated in the tumor regions during BNCT treatment. The selective killing of tumor cells and the destruction of the blood vessels in tumor masses may be responsible for the success of BA-mediated BNCT for liver tumors.
Subject(s)
Boric Acids/chemistry , Boron Neutron Capture Therapy , Liver Neoplasms, Experimental/radiotherapy , Animals , Autoradiography , Liver Neoplasms, Experimental/blood supply , Liver Neoplasms, Experimental/pathology , RabbitsABSTRACT
To introduce our preliminary experience of treating locally and regionally recurrent Head and Neck cancer patients at Tsing Hua Open-Pool Reactor in Taiwan, four patients (M/F=3/1, median age 68 Y/O) were enrolled. BNCT with BPA (400 mg/kg) injected in 2 phases and prescription dose of 12-35 Gy (Eq.)/fraction for 2 fractions at 30 day interval can be given with sustained blood boron concentration and tolerable early toxicities for recurrent H & N cancer.
Subject(s)
Boron Neutron Capture Therapy , Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Aged , Boron Neutron Capture Therapy/adverse effects , Female , Humans , Male , Multimodal Imaging , Neoplasm Recurrence, Local , Positron-Emission Tomography , Taiwan , Tomography, X-Ray ComputedABSTRACT
Osteosarcoma is a malignant tumor commonly found in human and animals. The ability of boric acid (BA) to accumulate in osteosarcoma due to the mechanism of the bone formation of cancer cells would make boron neutron capture therapy (BNCT) an alternative therapy for osteosarcoma. This study evaluated the feasibility of using BA as the boron drug for BNCT of bone cancer. The cytotoxicity of BA to L929 cells exceeded that of UMR-106 cells. With 25 µg (10)B/mL medium of BA treatment, the boron concentration in UMR-106 cells was higher than that in L929 cells. The biodistribution and pharmacokinetics of BA in Sprague-Dawley (SD) rats were studied by administrating 25 mg (10)B/kg body weight to SD rats. Blood boron level decreased rapidly within one hour after BA injection. Boron concentration in the long bone was 4-6 time higher than that of blood. Results of this study suggest that BA may be a potential drug for BNCT for osteosarcoma.
Subject(s)
Bone Neoplasms/radiotherapy , Boric Acids/therapeutic use , Boron Neutron Capture Therapy , Osteosarcoma/radiotherapy , Animals , Boric Acids/pharmacokinetics , Cell Line, Tumor , Male , Rats , Rats, Sprague-Dawley , Tissue DistributionABSTRACT
In this article, we will consider several core configurations and run the core calculation with MCNP to obtain the neutrons distribution at THOR. The thermal neutron flux inside the vertical tubes (VT-B-VT-E) and the fast neutron flux in the first row facing to the boron neutron capture therapy (BNCT) facility (I3-I5) were tallied for indication. Based on these simulation results, the fuel elements were rearranged during the annual repair period in 2007. The epithermal neutron flux at the center of BNCT beam exit in air was measured again, and the results showed that the beam intensity increased by 50%. Comparing the neutron intensities both in reactor core and at the BNCT beam exit for several core configurations, the results show that the BNCT beam intensity can be increased without decreasing the neutron intensity in core.
Subject(s)
Boron Neutron Capture Therapy/instrumentation , Nuclear Reactors , Biophysical Phenomena , Boron Neutron Capture Therapy/statistics & numerical data , Energy Transfer , Facility Design and Construction , Fast Neutrons/therapeutic use , Humans , Models, Statistical , Monte Carlo Method , TaiwanABSTRACT
The purpose of this work is to establish a method for evaluating the burn-up values of the rod-type TRIGA spent fuel by using gamma-ray spectrometry of the short-lived fission products 97Zr/97Nb, 132I, and 140La. Fuel irradiation history is not needed in this method. Short-lived fission-product activities were established by reirradiating the spent fuels in a nuclear reactor. Based on the measured activities, 235U burn-up values can be deduced by iterative calculations. The complication caused by 239Pu production and fission is also discussed in detail. The burn-up values obtained by this method are in good agreement with those deduced from the conventional method based on long-lived fission products 137Cs, 134Cs/137Cs ratio and 106Ru/137Cs ratio.
